Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin

被引:71
作者
De Schryver, ELLM [1 ]
机构
[1] Univ Utrecht Hosp, Trial Off Neurol, Utrecht, Netherlands
关键词
stroke; ischaemic; secondary prevention; trial;
D O I
10.1159/000016044
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The ESPRIT trial addresses the problem that aspirin, the standard therapy for secondary prevention of vascular complications after a transient ischaemic attack (TIA) or ischaemic stroke of arterial origin, reduces the risk of serious vascular events by only about 13%. Anticoagulants may be an alternative, as these have proved highly efficacious in trials after myocardial infarction and after cerebral ischaemia with atrial fibrillation. After cerebral ischaemia of presumed arterial origin, high-intensity anticoagulation (INH 3.0-4.5) is not safe, but the value of anticoagulation with an INR between 2.0 and 3.0 is still unknown; Secondly, a recent, large trial showed that the combination of aspirin and dipyridamole prevents more major vascular events than aspirin alone, but several earlier trials did not find such an advantage. In ESPRIT, patients with a TIA or minor ischaemic stroke (Rankin grade less than or equal to 3) will be randomized between oral anticoagulation (INR 2.0-3.0), the combination of dipyridamole (400 mg daily) plus aspirin (in any dose between 30 and 325 mg daily) and aspirin only. Primary outcome is the composite event 'death from all vascular causes, non-fatal stroke, non-fatal myocardial infarction or major bleeding complication', whichever occurs first. Outcome assessment will be blinded. The recruitment of a total of 4,500 patients from more than 10 countries is planned; the mean follow-up will be 3 years. Copyright (C) 2000 S. Karger AG. Basel.
引用
收藏
页码:147 / 150
页数:4
相关论文
共 31 条
[1]   Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia [J].
Algra, A ;
vanGijn, J .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 60 (02) :197-199
[2]   SCIENCE UNBLINDED [J].
ALGRA, A ;
VANGIJN, J .
LANCET, 1994, 343 (8904) :1040-1040
[3]   Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin [J].
Algra, A ;
Van Gijn, J .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (02) :255-255
[4]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[5]  
[Anonymous], 1994, Lancet, V343, P499
[6]   INTEROBSERVER AGREEMENT FOR THE ASSESSMENT OF HANDICAP IN STROKE PATIENTS [J].
BAMFORD, JM ;
SANDERCOCK, PAG ;
WARLOW, CP ;
SLATTERY, J .
STROKE, 1989, 20 (06) :828-828
[7]  
BOISSEL JP, 1982, NEW ENGL J MED, V307, P701
[8]   AICLA CONTROLLED TRIAL OF ASPIRIN AND DIPYRIDAMOLE IN THE SECONDARY PREVENTION OF ATHERO-THROMBOTIC CEREBRAL-ISCHEMIA [J].
BOUSSER, MG ;
ESCHWEGE, E ;
HAGUENAU, M ;
LEFAUCCONNIER, JM ;
THIBULT, N ;
TOUBOUL, D ;
TOUBOUL, PJ .
STROKE, 1983, 14 (01) :5-14
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   European stroke prevention study .2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke [J].
Diener, HC ;
Cunha, L ;
Forbes, C ;
Sivenius, J ;
Smets, P ;
Lowenthal, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1996, 143 (1-2) :1-13